Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 3/20 | 0.45 |
| ▸ | GRM8 | O00222 | 1/20 | 0.43 |
| ▸ | GRM6 | O15303 | 1/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | SLC1A5 | Q15758 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7997958 | 0.83 | USP2 (0.44) | KIF11POLB | |
| SCHEMBL28373111 | 0.83 | USP2 (0.44) | KIF11POLB | |
| SCHEMBL1702915 | 0.82 | ACLY (0.51) | — | |
| SCHEMBL2926805 | 0.77 | KIF11 (0.55) | KIF11GRM8GRM6GRM4 | |
| SCHEMBL28463183 | 0.77 | KIF11 (0.55) | KIF11GRM8GRM6GRM4 | |
| SCHEMBL1238414 | 0.77 | KIF11 (0.55) | KIF11GRM8GRM6GRM4 | |
| SCHEMBL22445010 | 0.77 | KIF11 (0.51) | KIF11GRM8GRM6GRM4SLC1A5 | |
| SCHEMBL429892 | 0.76 | SLC6A2 (0.51) | KIF11SLC1A5POLB | |
| SCHEMBL9171233 | 0.75 | ESR1 (0.43) | POLBMTNR1A | |
| SCHEMBL27304684 | 0.75 | ESR1 (0.46) | POLBMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883963-B2 | Peptidomimetics with glucagon antagonistic and GLP 1 agonistic activities | CADILA HEALTHCARE LIMITED (IN) | 2014-11-11 | — | — | US | disclosed |
| EP-2231701-B1 | PEPTIDOMIMETICS WITH GLUCAGON ANTAGONISTIC AND GLP-1 AGONISTIC ACTIVITIES | CADILA HEALTHCARE LTD (IN) | 2012-04-18 | — | — | EP | disclosed |
| US-20120021972-A1 | PEPTIDOMIMETICS WITH GLUCAGON ANTAGONISTIC AND GLP 1 AGONISTIC ACTIVITIES | CADILA HEALTHCARE LIMITED (IN) | 2012-01-26 | — | — | US | disclosed |
| EP-2231701-A2 | PEPTIDOMIMETICS WITH GLUCAGON ANTAGONISTIC AND GLP-1 AGONISTIC ACTIVITIES | Cadila Healthcare Limited (IN) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009125424-A2 | PEPTIDOMIMETICS WITH GLUCAGON ANTAGONISTIC AND GLP-1 AGONISTIC ACTIVITIES | CADILA HEALTHCARE LIMITED (IN) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021972-A1 | PEPTIDOMIMETICS WITH GLUCAGON ANTAGONISTIC AND GLP 1 AGONISTIC ACTIVITIES | GLP1R, GPR119, GIPR | KIF11 2313/4885GRM8 1344/4885GRM6 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.